Neonatal Drug Therapy Manual

Amphotericin B Lipid Complex

Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Updated March 5, 2024 - 2:32pm

Alternate Name(s): 
Abelcet
Classification: 
Antifungal
Original Date: 
August 2003
Revised Date: 
Indications: 
  • Treatment of severe systemic fungal infections and/or deep mycoses in patients:
    • who fail to respond to conventional amphotericin B
    • who develop nephrotoxicity after conventional amphotericin B
    • in whom conventional amphotericin B is contraindicated because of renal impairment
Administration: 
  • IV intermittent infusion: over 2 hours
Dosage: 
  • 2.5 - 5 mg/kg/day once daily
Side Effects: 
  • CNS: fever
  • CVS: hypotension, arrhythmias
  • Endocrine and metabolic: hypokalemia, hypomagnesemia
  • Hematologic: thrombocytopenia, leukopenia, anemia
  • Renal: increased serum creatinine, renal tubular acidosis, azotemia
Parameters to Monitor: 
  • Serum creatinine, urea, urine output
  • Serum potassium and serum magnesium
  • CBC
Reconstitution and Stability: 

N/A

Compatibility: 

- Solutions Compatible: D5W

- Incompatible: Do not mix with saline-precipitation occurs.  Do not mix with other drugs

Notes: 
  • Less toxic than conventional amphotericin B
References: 

-Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook 9th-11th Editions. Hudson: Lexi-Comp Inc.; 2002-2004.

-Trissel LA. Handbook on Injectable Drugs. 12th-13th Editions. Bethesda: American Society of Health-System Pharmacists; 2003-2005.

-The Childrens Hospital of Eastern Ontario Parenteral Drug Manual. Department of Pharmacy 2003.

 

 

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.